DOR/3TC/TDF

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC, University Health Network, Toronto, Prism Health North Texas, José Antonio Mata Marín

Conditions

ARTBMDBody Weight ChangesFastingHIV - Human Immunodeficiency VirusHivHuman Immunodeficiency VirusHuman Immunodeficiency Virus (HIV) Infection

Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

RecruitingNCT04375800

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus (HIV) Infection

Start: 2021-02-03End: 2034-04-11Target: 84Updated: 2026-02-24

Phase 3

Doravirine and Weight Gain in Antiretroviral Naive

WithdrawnNCT05457530

Prism Health North TexasART, BMD, Body Weight Changes +5

Start: 2022-08-01End: 2023-05-03Updated: 2023-05-12

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

RecruitingNCT07075146

José Antonio Mata MarínHIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity

Start: 2025-05-05End: 2028-08-01Target: 306Updated: 2025-08-24

Phase 4

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

TerminatedNCT04665375

University Health Network, TorontoHiv, Weight Gain

Start: 2021-04-26End: 2024-03-31Updated: 2025-07-16